This ASX 200 giant is about to wake up from a 3-year slumber. Are you ready?

This healthcare stock has been dormant for quite a while. But one expert reckons it's ready to break out for long-term investors.

| More on:
A man wakes up happy with a smile on his face and arms outstretched.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A large-cap S&P/ASX 200 Index (ASX: XJO) stock, after not doing much for three years, is about to rocket.

That's the opinion of Fairmont Equities managing director Michael Gable, who said CSL Limited (ASX: CSL)'s one-year forward PE ratio of 28 is at the lower end of its 5-year range.

"With the current multiple looking undemanding in the context of forecast earnings per share growth of ~20% over FY22 to FY25 on a compound annual growth rate (CAGR) basis, we consider CSL to be an attractive investment at current levels."

The CSL share price is still around 16% lower than its pre-COVID high reached in February 2020.

"The large consolidation from the past 3 years could be almost ending and that should lead to the stock resuming its longer-term uptrend," Gable said on the Fairmont blog.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

While the current labels remain an "attractive buy", conviction would be even higher once the stock rockets to the next milestone.

"An upside break above $300 would be the next buy signal."

Why is CSL an exciting long-term buy?

Gable cited some key catalysts on the horizon that could bear fruit for CSL investors.

"We consider the key catalysts for the shares to be: upside risk to gross profit margin expansion for CSL Behring over FY24 and FY25, further progress on the R&D product pipeline, and future results to validate the expected earnings growth contribution from the Vifor acquisition."

Vifor's numbers have already looked very positive, he added.

"Vifor's sales performance in 1H23 surprised on the upside, with CSL re-iterating all prior guidance, including its cost synergy target of US$75 million over three years remaining on track."

While raking in decent earnings from its mature businesses such as plasma collection, CSL is developing new products in the research lab.

"There are several potentially positive catalysts likely to emerge from the R&D product pipeline over the near term."

The four product-in-progress milestones Gable looks forward to are:

  • CSL112: currently in phase III trials, expected to launch early 2024
  • Hemgenix: US launch expected in "the near term"
  • Garadacimab for hereditary angioedema attacks: phase III data to be released soon
  • New plasma collection nomogram trial: expected to start this quarter

CSL shares are currently popular among the professional community. According to CMC Markets, 16 out of 19 analysts are rating it as a buy.

Motley Fool contributor Tony Yoo has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Senior man wearing glasses and a leather jacket works on his laptop in a cafe.
Broker Notes

Should I still swap my CSL for CBA shares or has the market corrected?

The two stocks have travelled opposite directions this month.

Read more »

Man with rocket wings which have flames coming out of them.
Resources Shares

Why Macquarie expects this ASX All Ords copper stock could surge 38%

With costs coming in below expectations, this ASX All Ords copper stock could rocket higher over the coming months.

Read more »

woman holding 'hiring' sign in shop
Broker Notes

Can you guess whether Macquarie prefers REA Group, CAR Group or SEEK shares?

Which ASX online classifieds business offers the best investment opportunity today?

Read more »

Female miner smiling in front of a mining vehicle as the Pilbara Minerals share price rises
Broker Notes

Expert says this ASX All Ords small cap mining stock could rocket 38%

Big upside ahead?

Read more »

Two laughing young women hold shopping bags and ride an escalator up to another level in a Scentre Group shopping centre.
Broker Notes

3 ASX consumer sector shares to buy in July: expert

A leading expert has named its top 3 picks.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Broker says WiseTech shares can hit $135

Bell Potter has good things to say about this rebounding tech stock.

Read more »

a man holds a firework sparkler in both hands as a shower of sparkly confetti falls from the sky around him as he smiles and closes his eyes in a celebratory scene.
Broker Notes

Stock market outlook: Macquarie 'ready to party like its 1999'

It may not be too late to invest in the share market according to the broker.

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Broker Notes

The smartest Australian stocks to buy with $400 right now

Let's see why these shares are highly rated by brokers.

Read more »